DEBA PHARMA
ActiveFinancials · financial year 2025, full format
Annual accounts 2025 filed on 24-07-2026 at the NBB all 37 filings
Turnover
≈ €5.0m
Estimated: probably between €3.4m and €8.3m
EBIT margin
Not included in this filing
Net result
€2.1m▲ 15.8%
2024 · €1.8m
Working capital
€5.0m▲ 3.8%
2024 · €4.8m
Multi-year overview
2018 to 2025, 8 financial yearsOperating result
€2.7m
▲ 16.4%
2025
20182025
Net result
€2.1m
▲ 15.8%
2025
middle half of the sector
20182025
Equity
€6.2m
▲ 4.0%
2025
middle half of the sector
20182025
Total assets
€6.6m
▲ 3.2%
2025
middle half of the sector
20182025
Debt
€339,319
▼ 7.8%
2025
20182025
Working capital
€5.0m
▲ 3.8%
2025
middle half of the sector
20182025
Solvency
94.4%
▲ 0.7pp
2025
highest quarter of the sector
20182025
Current ratio
15.87
▲ 1.00
2025
highest quarter of the sector
20182025
Return on assets (ROA)
31.9%
▲ 3.5pp
2025
highest quarter of the sector
20182025
Staff (FTE)
1.2
▲ 71.4%
2025
lowest quarter of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.6m-€1.1m▲ 74.4%€1.6m▲ 40.3%€1.5m▼ 1.6%€1.9m▲ 22.4%€2.0m▲ 5.3%€2.3m▲ 17.8%€2.7m▲ 16.4%
Net result€0.5m-€0.8m▲ 58.2%€1.2mabove the sector's middle half▲ 46.7%€1.2mabove the sector's middle half▼ 1.7%€1.4mabove the sector's middle half▲ 21.6%€1.5mabove the sector's middle half▲ 7.7%€1.8mabove the sector's middle half▲ 18.6%€2.1mwithin the sector's middle half▲ 15.8%
Equity€2.5m-€2.5m▼ 0.1%€3.7mabove the sector's middle half▲ 45.1%€4.5mabove the sector's middle half▲ 24.1%€5.3mabove the sector's middle half▲ 16.7%€5.7mabove the sector's middle half▲ 7.9%€6.0mabove the sector's middle half▲ 4.4%€6.2mwithin the sector's middle half▲ 4.0%
Total assets€3.4m-€4.0m▲ 15.1%€4.3mabove the sector's middle half▲ 9.9%€5.2mabove the sector's middle half▲ 19.0%€5.9mabove the sector's middle half▲ 14.0%€6.4mabove the sector's middle half▲ 8.2%€6.4mabove the sector's middle half▼ 0.3%€6.6mwithin the sector's middle half▲ 3.2%
Debt€0.9m-€1.4m▲ 49.6%€0.6m▼ 53.0%€0.6m▼ 7.6%€0.6m▼ 5.2%€0.6m▲ 12.8%€0.4m▼ 42.2%€0.3m▼ 7.8%
Working capital€1.2m-€1.3m▲ 6.2%€2.4mabove the sector's middle half▲ 81.7%€3.3mabove the sector's middle half▲ 38.1%€4.0mabove the sector's middle half▲ 23.8%€4.5mabove the sector's middle half▲ 12.4%€4.8mabove the sector's middle half▲ 5.9%€5.0mwithin the sector's middle half▲ 3.8%
Solvency73.3%-63.7%▼ 9.6pp84.0%above the sector's middle half▲ 20.4pp87.6%above the sector's middle half▲ 3.6pp89.7%above the sector's middle half▲ 2.1pp89.5%above the sector's middle half▼ 0.3pp93.7%above the sector's middle half▲ 4.3pp94.4%above the sector's middle half▲ 0.7pp
Current ratio3.75-2.33▼ 1.428.31above the sector's middle half▲ 5.9810.34above the sector's middle half▲ 2.0310.07above the sector's middle half▼ 0.279.06above the sector's middle half▼ 1.0114.86above the sector's middle half▲ 5.8015.87above the sector's middle half▲ 1.00
Return on assets (ROA)14.9%-20.4%▲ 5.6pp27.3%above the sector's middle half▲ 6.8pp22.5%above the sector's middle half▼ 4.7pp24.0%above the sector's middle half▲ 1.5pp23.9%above the sector's middle half▼ 0.1pp28.5%above the sector's middle half▲ 4.5pp31.9%above the sector's middle half▲ 3.5pp
Staff (FTE)0.20.5▲ 150%0.5=0.5below the sector's middle half=0.5below the sector's middle half=0.7below the sector's middle half▲ 40.0%1.2below the sector's middle half▲ 71.4%
above
within
below
The sector band is the middle half of the companies in Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 16% higher than in 2024 and the highest since 2021. It is the fourth rise in a row.
The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €6.6m
Fixed assets
€1.3m ▲ 3.0%
Current assets
€5.3m ▲ 3.3%
Equity and liabilities €6.6m
Equity
€6.2m ▲ 4.0%
Provisions
€28,563 ▼ 10.5%
Debt
€339,319 ▼ 7.8%
Debt's share of the balance-sheet total falls from 5.8% to 5.2%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€2.8m▲
2024 · €2.5m
Cash flow
€2.2m▲
2024 · €1.9m
Quick ratio
12.01▲
2024 · 11.03
Debt to equity
0.05▼
2024 · 0.06
ROE
33.8%▲
2024 · 30.4%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€334,814▼
2024 · €346,038
Debt > 1 year
€0▼
2024 · €20,833
Income taxes
€684,156▲
2024 · €593,551
Staff costs
€57,576▲
2024 · €33,612
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 31-12-2021 | 31-12-2022 | 31-12-2023 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 1 | 1 | 1 | 2 | 2 |
| full-time | - | - | 0 | 0 | 0 |
| part-time | 1 | 1 | 1 | 2 | 2 |
| in full-time equivalents | 0.5 | 0.5 | 0.5 | 1.2 | 1.2 |
| Average over the year, in full-time equivalents | 0.5 | 0.5 | 0.5 | 0.7 | 1.2 |
| On a permanent contract | 1 | 1 | 1 | 2 | 2 |
| Joined | 1 | - | - | 1 | 0 |
| Left | 1 | - | - | 0 | 0 |
| Training hours | - | - | - | - | 0 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Securities and guarantees
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Debts secured on the company's own assets | €322,917 | €170,833 | €120,833 | €70,833 | €20,833 |
| Mortgage mandates | €750,000 | €750,000 | €750,000 | €750,000 | €750,000 |
| Carrying value of the mortgaged assets | €1.4m | €1.3m | €1.2m | €1.1m | €1.1m |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €31,931 | €1,450 | €11,015 | €71,882 | €172,971 |
| Intangible fixed assets | €37,129 | - | - | - | - |
| Depreciation and write-downs of the year | €166,597 | €150,601 | €142,095 | €133,935 | €127,698 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Subsidies and aid
Flemish government
2022 to 2025 · 4 entries · €13,499 awarded · €10,198 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 1 | €4,980 | €3,045 |
| 2024 | 1 | €0 | €6,134 |
| 2023 | 1 | €7,500 | €0 |
| 2022 | 1 | €1,019 | €1,019 |
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | - | €0.007m | €0.02m | ▲ 152% |
| Remuneration, social security and pensions62 | - | - | - | €0.02m | €0.02m | €0.02m | €0.03m | €0.06m | ▲ 71.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | €0.1m | ▼ 4.7% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | - | - | €0.02m | €0 | -€0.02m | - |
| Other operating charges640/8 | - | - | - | €0.02m | €0.01m | €0.02m | €0.02m | €0.04m | ▲ 127% |
| Gross operating margin9900 | €0.8m | €1.3m | €1.8m | €1.7m | €2.1m | €2.2m | €2.5m | €2.9m | ▲ 15.9% |
| Operating profit (loss)9901 | €0.6m | €1.1m | €1.6m | €1.5m | €1.9m | €2.0m | €2.3m | €2.7m | ▲ 16.4% |
| Financial income75/76B | - | - | - | €0.004m | €0.001m | €0.05m | €0.07m | €0.06m | ▼ 7.8% |
| Recurring financial income75 | €0.007m | €0.005m | €0.005m | €0.003m | €0.001m | €0.05m | €0.07m | €0.06m | ▼ 7.8% |
| Non-recurring financial income76B | - | - | - | €0.001m | - | - | - | - | - |
| Financial charges65/66B | - | - | - | €0.005m | €0.004m | €0.003m | €0.002m | €0.001m | ▼ 31.9% |
| Recurring financial charges65 | €0.008m | €0.007m | €0.006m | €0.005m | €0.004m | €0.003m | €0.002m | €0.001m | ▼ 31.9% |
| Profit (loss) for the period before taxes9903 | €0.6m | €1.1m | €1.6m | €1.5m | €1.9m | €2.0m | €2.4m | €2.8m | ▲ 15.7% |
| Transfer from deferred taxes780 | - | - | - | €0.005m | €0.004m | €0.004m | €0.004m | €0.003m | ▼ 5.9% |
| Income taxes67/77 | €0.1m | €0.2m | €0.4m | €0.4m | €0.5m | €0.5m | €0.6m | €0.7m | ▲ 15.3% |
| Profit (loss) for the period9904 | €0.5m | €0.8m | €1.2m | €1.2m | €1.4m | €1.5m | €1.8m | €2.1m | ▲ 15.8% |
| Transfer from tax-exempt reserves789 | - | - | - | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | ▼ 5.9% |
| Profit (loss) for the period to be appropriated9905 | €0.5m | €0.7m | €1.2m | €1.2m | €1.4m | €1.5m | €1.8m | €2.1m | ▲ 15.7% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €3.4m | €4.0m | €4.3m | €5.2m | €5.9m | €6.4m | €6.4m | €6.6m | ▲ 3.2% |
| Fixed assets21/28 | €1.8m | €1.7m | €1.7m | €1.6m | €1.4m | €1.3m | €1.2m | €1.3m | ▲ 3.0% |
| Intangible fixed assets21 | €0.001m | €0.001m | €339 | €0.03m | €0.03m | €0.02m | €0.01m | €0.004m | ▼ 65.3% |
| Tangible fixed assets22/27 | €1.8m | €1.7m | €1.7m | €1.5m | €1.4m | €1.3m | €1.2m | €1.3m | ▲ 3.7% |
| Land and buildings22 | - | - | - | €1.4m | €1.3m | €1.2m | €1.1m | €1.1m | ▼ 0.7% |
| Furniture and vehicles24 | - | - | - | €0.2m | €0.1m | €0.09m | €0.1m | €0.1m | ▲ 53.3% |
| Current assets29/58 | €1.7m | €2.3m | €2.7m | €3.6m | €4.5m | €5.1m | €5.1m | €5.3m | ▲ 3.3% |
| Stocks and contracts in progress3 | €0.6m | €0.6m | €0.6m | €0.8m | €1.2m | €1.5m | €1.3m | €1.3m | ▼ 2.7% |
| Stocks30/36 | - | - | - | €0.8m | €1.2m | €1.5m | €1.3m | €1.3m | ▼ 2.7% |
| Amounts receivable within one year40/41 | €0.3m | €0.3m | €0.8m | €0.7m | €0.7m | €0.6m | €0.5m | €0.7m | ▲ 39.5% |
| Trade receivables40 | - | - | - | €0.7m | €0.7m | €0.5m | €0.5m | €0.7m | ▲ 37.5% |
| Other amounts receivable41 | - | - | - | €0.002m | €0.001m | €0.04m | €0 | €0.01m | - |
| Current investments50/53 | - | - | - | - | - | €1.5m | €1.0m | €1.9m | ▲ 88.1% |
| Cash at bank and in hand54/58 | €0.7m | €1.4m | €1.2m | €2.1m | €2.6m | €1.6m | €2.3m | €1.3m | ▼ 40.5% |
| Deferred charges and accrued income490/1 | - | - | - | €0.02m | €0.04m | €0.04m | €0.02m | €0.04m | ▲ 88.8% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €3.4m | €4.0m | €4.3m | €5.2m | €5.9m | €6.4m | €6.4m | €6.6m | ▲ 3.2% |
| Equity10/15 | €2.5m | €2.5m | €3.7m | €4.5m | €5.3m | €5.7m | €6.0m | €6.2m | ▲ 4.0% |
| Contributions10/11 | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Capital10 | - | - | - | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Issued capital100 | - | - | - | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Revaluation surpluses12 | - | - | - | €0.06m | €0.06m | €0.06m | €0.06m | €0.06m | = |
| Reserves13 | €2.4m | €2.4m | €3.5m | €4.4m | €5.2m | €5.6m | €5.8m | €6.1m | ▲ 4.1% |
| Non-distributable reserves130/1 | - | - | - | €0.006m | €0.006m | €0.006m | €0.006m | €0.006m | = |
| Legal reserve130 | - | - | - | €0.006m | €0.006m | €0.006m | €0.006m | €0.006m | = |
| Tax-exempt reserves132 | - | - | - | €0.1m | €0.1m | €0.1m | €0.1m | €0.09m | ▼ 10.4% |
| Distributable reserves133 | - | - | - | €4.3m | €5.0m | €5.5m | €5.7m | €6.0m | ▲ 4.3% |
| Profit (loss) carried forward14 | - | - | - | - | - | €0 | €0 | €0 | - |
| Provisions and deferred taxes16 | - | €0.06m | €0.05m | €0.04m | €0.04m | €0.04m | €0.03m | €0.03m | ▼ 10.5% |
| Deferred taxes168 | - | - | - | €0.04m | €0.04m | €0.04m | €0.03m | €0.03m | ▼ 10.5% |
| Amounts payable17/49 | €0.9m | €1.4m | €0.6m | €0.6m | €0.6m | €0.6m | €0.4m | €0.3m | ▼ 7.8% |
| Amounts payable after more than one year17 | €0.5m | €0.4m | €0.3m | €0.2m | €0.1m | €0.07m | €0.02m | €0 | ▼ 100% |
| Financial debts170/4 | - | - | - | €0.2m | €0.1m | €0.07m | €0.02m | €0 | ▼ 100% |
| Amounts payable within one year42/48 | €0.4m | €1.0m | €0.3m | €0.3m | €0.4m | €0.6m | €0.3m | €0.3m | ▼ 3.2% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.08m | €0.05m | €0.05m | €0.05m | €0.02m | ▼ 58.3% |
| Financial debts43 | - | - | - | €0.001m | - | - | - | - | - |
| Credit institutions430/8 | - | - | - | €0.001m | - | - | - | - | - |
| Trade debts44 | €0.3m | €0.08m | €0.2m | €0.2m | €0.3m | €0.4m | €0.2m | €0.2m | ▼ 10.5% |
| Suppliers440/4 | - | - | - | €0.2m | €0.3m | €0.4m | €0.2m | €0.2m | ▼ 10.5% |
| Taxes, remuneration and social security45 | - | - | - | €0.05m | €0.08m | €0.05m | €0.04m | €0.08m | ▲ 91.6% |
| Taxes450/3 | - | - | - | €0.05m | €0.08m | €0.05m | €0.04m | €0.08m | ▲ 93.1% |
| Remuneration and social security454/9 | - | - | - | €0.002m | €0.002m | €0.002m | €0.003m | €0.005m | ▲ 69.0% |
| Other amounts payable47/48 | - | - | - | €0.06m | €0.06m | €0.07m | €0.06m | €0.06m | ▼ 4.1% |
| Accrued charges and deferred income492/3 | - | - | - | - | - | €0.005m | €0.001m | €0.005m | ▲ 234% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.5m | €0.8m | €1.2m | €1.2m | €1.4m | €1.5m | €1.8m | €2.1m | ▲ 15.8% |
| + Depreciation and write-downs630 | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | €0.1m | €0.1m | €0.1m | ▼ 4.7% |
| Operating cash flow (approximation) | €0.7m | €1.0m | €1.3m | €1.3m | €1.6m | €1.7m | €1.9m | €2.2m | ▲ 14.4% |
| Investment in fixed assets (approximation) | - | -€0.1m | -€0.1m | -€0.07m | -€0.001m | -€0.01m | -€0.06m | -€0.2m | ▼ 165% |
| Change in cash | - | €0.6m | -€0.1m | €0.8m | €0.5m | -€1.0m | €0.7m | -€0.9m | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 31,368 companies had the same profile as DEBA PHARMA has now. Two years later, 93.5% were still going and 0.5% had gone bankrupt.
- Micro
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
93.5%
was still going
5.9%
stopped otherwise
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of DEBA PHARMA itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for DEBA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 37 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 24-07-2026 | 2026-00329263 | |
| 31-12-2024 | abbreviated format | 14-07-2025 | 2025-00264369 | |
| 31-12-2023 | abbreviated format | 27-07-2024 | 2024-00292440 | |
| 31-12-2022 | abbreviated format | 19-07-2023 | 2023-00249552 | |
| 31-12-2021 | abbreviated format | 18-07-2022 | 2022-20194292 | |
| 31-12-2020 | abbreviated format | 08-07-2021 | 2021-32300039 | |
| 31-12-2019 | abbreviated format | 16-06-2020 | 2020-16900405 | |
| 31-12-2018 | abbreviated format | 17-07-2019 | 2019-33300281 | |
| 31-12-2017 | abbreviated format | 12-07-2018 | 2018-31500199 | |
| 31-12-2016 | abbreviated format | 26-07-2017 | 2017-35200447 |